battle of patentGiven the robust claims of Spruce's US Patent No. 11,344,557 and Neurocrine's stock chart performance, the patent's invalidation would likely be both challenging and detrimental to the plaintiff.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.761 CHF
309.97 M CHF
2.14 B CHF
96.49 M
About Neurocrine Biosciences, Inc.
Sector
Industry
CEO
Kyle W. Gano
Website
Headquarters
San Diego
Founded
1992
ISIN
US64125C1099
FIGI
BBG00LVF08S7
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Related stocks
Neurocrine Stock Quote | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Neurocrine Stock Quote
- Double Formation
* 155.00 USD | 1st Area Of Value | Subdivision 1
* A+ Set Up)) | Completed Survey
- Triple Formation
* 130.00 USD | 2nd Area Of Value | Subd
Neurocrine Stock Quote | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# Neurocrine Stock Quote
- Double Formation
* Retracement | Not Numbered | A+ Set Up Area | Subdivision 1
* Wedge Structure | 117.00 USD & 106.00 USD | Subdivision 2
- Triple Formatio
NBIX -Long -TP>25%NASDAQ:NBIX
- LONG - RISK 1/5 - TP > 25%
We already have a buy position.
Good luck to everyone...
==============================
NBIX -Long -TP>25%NASDAQ:NBIX
-Long
-TP>25-30% and more
-waiting for a point to enter a long position
Solid Growth but Misses Q2 Earnings TargetsNeurocrine Biosciences Inc. (NASDAQ: NBIX) is continuing to advance its position in the biotech sector, despite facing a slight setback in its Q2 2024 earnings report. The company posted revenue of $590.2 million, which was higher than analyst estimates of $545.9 million, representing a 30.4% year-o
Textbook bullish flagIt looks like a beautiful flag (or pennant) to me, with high volume at the pole and the volume drying up during the consolidation.
I am expecting continuation.
(Potential Trade) NBIX(13 May 2024)
Disclaimer:
All information posted are the author's own trades/potential trades.
The author is not a certified Financial Advisor and do not have the certifications to provide financial advice.
These information are strictly for educational purposes only and do not constitute any finan
NBIX Biotechnology / Pharmaceutical Pre-earnings LONGNeurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th.
Investor and trader interest seems to be moderately increasing in the past week. The combined
MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket
before 7:45 AM
"NBIX Stock Breaks All-Time Highs, Strong Buy Opportunity!"NBIX Stock Breaks All-Time Highs: A Strong Buy Opportunity Emerges
Neurocrine Biosciences Inc. (NBIX) is currently making waves in the stock market as it breaks out of its all-time highs, signaling a promising opportunity for investors. After 14 years of steady upward momentum and price consolidat
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NB3 is featured.
Frequently Asked Questions
The current price of NB3 is 89.100 CHF — it has increased by 0.40% in the past 24 hours. Watch Neurocrine Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Neurocrine Biosciences, Inc. stocks are traded under the ticker NB3.
We've gathered analysts' opinions on Neurocrine Biosciences, Inc. future price: according to them, NB3 price has a max estimate of 160.15 CHF and a min estimate of 99.30 CHF. Watch NB3 chart and read a more detailed Neurocrine Biosciences, Inc. stock forecast: see what analysts think of Neurocrine Biosciences, Inc. and suggest that you do with its stocks.
NB3 stock is 0.40% volatile and has beta coefficient of 0.67. Track Neurocrine Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Neurocrine Biosciences, Inc. there?
Today Neurocrine Biosciences, Inc. has the market capitalization of 11.33 B, it has increased by 3.67% over the last week.
Yes, you can track Neurocrine Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Neurocrine Biosciences, Inc. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
NB3 earnings for the last quarter are 0.84 CHF per share, whereas the estimation was 0.77 CHF resulting in a 9.89% surprise. The estimated earnings for the next quarter are 1.28 CHF per share. See more details about Neurocrine Biosciences, Inc. earnings.
Neurocrine Biosciences, Inc. revenue for the last quarter amounts to 545.46 M CHF, despite the estimated figure of 518.79 M CHF. In the next quarter, revenue is expected to reach 599.83 M CHF.
NB3 net income for the last quarter is 85.29 M CHF, while the quarter before that showed 6.99 M CHF of net income which accounts for 1.12 K% change. Track more Neurocrine Biosciences, Inc. financial stats to get the full picture.
No, NB3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 3, 2025, the company has 1.8 K employees. See our rating of the largest employees — is Neurocrine Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neurocrine Biosciences, Inc. EBITDA is 418.60 M CHF, and current EBITDA margin is 26.50%. See more stats in Neurocrine Biosciences, Inc. financial statements.
Like other stocks, NB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neurocrine Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.